Clinical trial · Observational
Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer
Application of an Automated Liquid Biopsy System in the Detection of Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting in low compliance. Stool based tests have limited sensitivity for the detection of precancerous lesions. The CMx platform has been showed to be able to the detection of Circulating Tumor Cells (CTCs) in high sensitivity and specificity. In published studies, circulating Tumor Cells (CTCs) are captured and quantified in advanced-stages of colorectal cancer. In order to detect early and pre-cancer circulating tumor cells, we have developed an Automated Liquid Biopsy Platform that improves the detection of CTCs in early cancer stages. Therefore, this study goals are: 1) to establish a standard detection process utilizing the Automated Liquid Biopsy Platform. 2) Parallel comparison of laboratory manual operation and Automated Liquid Biopsy Platform. 3) Verify the feasibility of use of an Automated Liquid Biopsy Platform in the clinical setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colo-rectal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Disease Group
- description
- The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.
- label
- Control Group
- description
- The control group will receive Colonoscopy
Primary outcomes (1)
- measure
- Detection of circulating tumor cells
- timeFrame
- Prior to treatment or colonoscopy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. The disease group is diagnosed with colorectal cancer 0-4 and has not been treated. * 2\. The control group will receive Colonoscopy * 3\. Above 20 years old Exclusion Criteria: * 1\. Refuse to sign the informed consent form * 2\. Received surgery within one month * 3\. Previous cancer history * 4\. Autoimmune diseases * 5\. Chronic inflammatory diseases * 6\. Acute inflammatory or infectious diseases in three months * 7\. Myelodysplastic syndromes and myeloproliferative disorder * 8\. Other diseases decided by PI
References
Publications (0)
Data not yet available